FIVE PRIME THERAPEUTICS INC Uncategorized Contracts & Agreements
24 Contracts & Agreements
- Form of Gross-Up Agreement (Filed With SEC on April 16, 2021)
- Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of April 16, 2020 (Filed With SEC on August 6, 2020)
- Offer Letter Agreement by and between the company and Thomas Civik, dated as of April 6, 2020 (Filed With SEC on August 6, 2020)
- Letter Agreement by and between the company and William R. Ringo, dated as of March 6, 2020 (Filed With SEC on May 7, 2020)
- Letter Agreement by and between the company and Helen Collins, dated as of December 12, 2019 (Filed With SEC on February 27, 2020)
- Letter Agreement by and between the company and David V. Smith, dated as of December 12, 2019 (Filed With SEC on February 27, 2020)
- Letter Agreement by and between the company and Francis Sarena, dated as of December 12, 2019 (Filed With SEC on February 27, 2020)
- Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of December 20, 2019 (Filed With SEC on February 27, 2020)
- Description of the Registrants Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 27, 2020)
- Amendment to Offer Letter Agreement by and between the company and William R. Ringo, dated as of October 8, 2019 (Filed With SEC on November 6, 2019)
- Offer Letter Agreement by and between the company and William R. Ringo, dated as of October 4, 2019 (Filed With SEC on November 6, 2019)
- Offer Letter Agreement by and between the company and David V. Smith, dated as of October 24, 2018 (Filed With SEC on February 26, 2019)
- Offer Letter Agreement by and between the company and Bryan Irving, dated as of July 27, 2017 (Filed With SEC on February 26, 2019)
- Offer Letter by and between the company and Helen Collins, dated as of May 12, 2016 (Filed With SEC on February 27, 2018)
- Offer Letter Agreement by and between the company and Lewis T. Williams, dated as of November 17, 2017 (Filed With SEC on February 27, 2018)
- Offer Letter by and between the Company and Aron Knickerbocker, dated as of October 18, 2017 (Filed With SEC on November 6, 2017)
- Five Prime Therapeutics, Inc. • Two Corporate Drive • South San Francisco, CA 94080 • Phone ###-###-#### • Fax ###-###-#### www.fiveprime.com (Filed With SEC on February 24, 2017)
- Five Prime Therapeutics,Inc. · Two Corporate Drive · South San Francisco, CA 94080 · Phone ###-###-#### · Fax ###-###-#### www.fiveprime.com (Filed With SEC on January 22, 2014)
- ANNEX SP SCHEDULE OF PAYMENTS TO NRC (Filed With SEC on December 9, 2013)
- TECHNOLOGY LICENCE AGREEMENT (Filed With SEC on August 23, 2013)
- Page 2 of8 (Filed With SEC on August 23, 2013)
- Indemnity Agreement (Filed With SEC on July 26, 2013)
- Five Prime Therapeutics, Inc. Two Corporate Drive South San Francisco, CA 94080 Main: (415) 365-5600 Fax: (415) 520-9842 (Filed With SEC on July 26, 2013)
- Five Prime Therapeutics, Inc. 1650 Owens Street, Suite 200 San Francisco, CA 94158 (Filed With SEC on July 26, 2013)
